Publications by authors named "Iin Narwanti"
A novel quinoid-based CDC25 phosphatase inhibitor against human lung adenocarcinoma across different models.
Biomed Pharmacother
August 2025
Cell division cycle 25 (CDC25) phosphatase is a key cell cycle regulator whose overexpression is linked to tumor malignancy and poor prognosis. Its inhibition suppresses cancer cell growth and induces cell death, making it a promising therapeutic target. In this study, we aimed to develop novel CDC25 inhibitors with therapeutic potential.
View Article and Find Full Text PDFArticle Synopsis
- Triple-negative breast cancer (TNBC) is difficult to treat due to its aggressive nature and limited effective therapies, prompting the need for new treatments.
- The study developed dual inhibitors targeting CDC25 and HDACs by combining specific molecular structures, showing that one compound, 18A, was particularly effective against TNBC cells while sparing non-cancerous cells.
- 18A demonstrated strong cytotoxic effects, inhibited key cell cycle proteins, triggered DNA damage, and induced cell death, highlighting its potential as a promising targeted therapy for TNBC that requires further research.
Disruptor of telomeric silencing 1-like (DOT1L) is a key hub in histone lysine methyltransferase and an attractive therapeutic target for treating hematological malignancies including acute myeloid leukemia (AML). In this study, we report the design and synthesis of a new series of adenosine derivatives as DOT1L inhibitors by accommodating a basic linker piperidine-4-ylmethyl motif to respective aryl-urea/benzimidazole scaffolds. The anti-DOT1L enzyme activity analysis demonstrated that compounds 8, 12, and 13 strongly suppressed DOT1L activity with IC values ranging from 0.
View Article and Find Full Text PDF6-Regioisomeric 5,8-quinolinediones as potent CDC25 inhibitors against colorectal cancers.
Eur J Med Chem
October 2023
Article Synopsis
- Precise control of the cell cycle is crucial for maintaining cell identity and preventing issues like tumor formation, with CDC25 phosphatases playing a key role in regulating cyclin-dependent kinases (CDKs).
- A series of derivatives of the CDC25 inhibitor, NSC663284, showed enhanced potency against colorectal cancer cells, particularly the 6-isomer of 5,8-quinolinedione (compound 6b), which exhibited strong antiproliferative activity.
- Compound 6b not only blocked cell cycle progression and induced DNA damage but also triggered apoptosis in cancer cells, highlighting its potential as a candidate for further development as an anti-colorectal cancer agent.